Fertility and Sterility
Volume 90, Issue 1 , Pages 17-22 , July 2008

Use of the levonorgestrel-releasing intrauterine system in breast cancer patients

  • Xuan Bich Trinh, M.D.

      Affiliations

    • Department of Obstetrics and Gynaecology, General Hospital St. Augustinus, Wilrijk, Belgium
    • Department of Gynaecologic Oncology, University Hospital Antwerp, Edegem, Belgium
    • Corresponding Author InformationReprint requests: Xuan Bich Trinh, M.D., Department of Obstetrics and Gynaecology, St. Augustinus General Hospital, Oosterveldlaan 24, 2610 Wilrijk, Belgium (FAX: 32-3-443-30-36).
    • ,
  • Wiebren A.A. Tjalma, M.D., Ph.D.

      Affiliations

    • Department of Gynaecologic Oncology, University Hospital Antwerp, Edegem, Belgium
    • ,
  • Amin P. Makar, M.D., Ph.D.

      Affiliations

    • Department of Gynaecologic Oncology, The Middelheim Hospital, Antwerp, Belgium
    • Department of Gynaecologic Oncology, University Hospital Ghent, Ghent, Belgium
    • ,
  • Guy Buytaert, M.D.

      Affiliations

    • Department of Obstetrics and Gynaecology, Klina Hospital, Brasschaat, Belgium
    • ,
  • Joost Weyler, M.D., Ph.D.

      Affiliations

    • Department of Epidemiology and Social Medicine, University of Antwerp, Wilrijk, Belgium
    • ,
  • Peter A. van Dam, M.D., Ph.D.

      Affiliations

    • Department of Obstetrics and Gynaecology, General Hospital St. Augustinus, Wilrijk, Belgium

Received 30 December 2006 ,Revised 29 May 2007 ,Accepted 29 May 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 P.A.v.D. participated in a phase III trial for Schering and has been an invited speaker for Schering, Organon, Astra Zeneca, and Novartis.

PII: S0015-0282(07)01200-9

doi: 10.1016/j.fertnstert.2007.05.033

Fertility and Sterility
Volume 90, Issue 1 , Pages 17-22 , July 2008

Article Tools

* Image Usage & Resolution